A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.
The Greater Nashville Venture Capital Association launches, uniting forces for Middle Tennessee startups and unveiling a new era in the region’s entrepreneurial ecosystem